NGL Fine-Chem Limited (NSE:NGLFINE)

Market Cap	17.11B +148.0%
Revenue (ttm)	5.16B +40.0%
Net Income	481.27M +127.8%
EPS	77.90 +127.8%
Shares Out	n/a
PE Ratio	35.56
Forward PE	n/a
Dividend	1.75 (0.06%)
Ex-Dividend Date	Aug 12, 2025

Volume	100,516
Average Volume	17,905
Open	2,569.80
Previous Close	2,501.90
Day's Range	2,288.50 - 2,879.80
52-Week Range	980.00 - 2,801.00
Beta	0.55
RSI	66.06
Earnings Date	May 21, 2026

About NGL Fine-Chem

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, rafoxanide, diminazene aceturate, s-methoprene, carprofen, diminazene diaceturate, ractopamine HCI, toltra...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1981
• Employees: 520
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: NGLFINE

Financial Performance

In fiscal year 2026, NGL Fine-Chem's revenue was 5.16 billion, an increase of 40.03% compared to the previous year's 3.68 billion. Earnings were 481.27 million, an increase of 127.83%.